Celldex Therapeutics is announcing preliminary results from their randomized Phase IIb EMERGE study evaluating the antibody drug conjugate CDX-011 (glembatumumab vedotin) in patients with glycoprotein NMB (GPNMB) expressing, advanced, heavily pretreated breast cancer.
These prelim results suggest that CDX-011 induces impressive response rates compared to current, available therapies in patients diagnosed with advanced, refractory breast cancers with high GPNMB expression (i.e. expression in greater-than or equal to twenty-five percent of tumor cells).
Treatment with CDX-011 resulted in an overall response rate (ORR) of 32 percent, compared to treatment with 'Investigator's Choice' (IC) single-agent chemotherapy, in which the ORR was just 13 percent.
CDX-011 further had a strong showing in patients with triple negative breast cancer across all levels of GPNMB expression where treatment options are currently limited, with an ORR of 21 percent compared to zero percent in IC.
Furthermore, patients with triple negative breast cancer who also had high GPNMB expression experienced an ORR of 36 percent compared to ORR in the IC arm, which was zero.
Based on these prelim data, Celldex believes that CDX-011 has real promise as a targeted therapy for certain breast cancer patients with high GPNMB expression, as well as those patients suffering from triple negative breast cancer.
Celldex says that they will update these results sometime in the fourth quarter of 2012.
Source: MarketWatch
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
